

UNKNOWN PRIMARY NEOPLASIA DX 2.0 REPORT

PATIENT INFORMATION

Identification Data		General Biochemistry		Biochemistry Realization	
HRN:	D0000000002	Creatinine (mg/dL):	1.60	Blood Drawn Date: 29-08-2017	
ID Card:	Unknown	ASAT (U/L):	21.00		
		ALAT (U/L):	13.00	Lifestyle	
		GGT (U/L):	67.00	Smoking Habits: Past	
Personal Data		Total Bilirubin (mg/dL):	0.80		
Gender:	Female	Hemolized Sample:	No		
Race:	Other				
Age:	87				
Comorbidities		Serum Tumor Markers			
Ascites:	No	AFP (ng/mL):	3.00		
BPH:	N/A	β-hCG (mU/mL):	2.00		
Cholestasis:	No	CA 15.3 (U/mL):	16.00		
Chronic Liver Disease:	No	CA 19.9 (U/mL):	129.00		
Jaundice:	No	CA 72.4 (U/mL):	85.00		
Metrorrhagia:	No	CA 125 (U/mL):	383.00		
Pancreatitis:	No	CEA (ng/mL):	190.00		
Pemphigus/Psoriasis:	No	CYFRA 21-1 (ng/mL):	114.00		
Pericardial/Pleural Effusion:	No	HE4 (pmol/L):	43.00		
Prostatitis:	N/A	NSE (ng/mL):	41.00		
Renal Failure:	Yes	ProGRP (pg/mL):	65.00		
		Total PSA (ng/mL):	0.00		
		fPSA (ng/mL):	0.00		
		SCC (mg/mL):	5.20		
		S100 (mg/mL):	0.00		

OUTCOME

Tumor Markers Results

Some Tumor Markers are outside the reference range and suggest malignancy.



Comments

Renal Failure is a well-known source of False Positive (FP) in healthy patients by increasing CEA levels but, these particular CEA levels suggest malignancy. Renal Failure is a well-known source of False Positive (FP) in healthy patients by increasing CYFRA levels but, these particular CYFRA levels suggest malignancy. Moderate increase of NSE that may be found in some benign diseases (such as Ascites,



Chronic Liver Disease, Jaundice or Renal Failure, among others). Moderate increase of ProGRP that may be found in some benign diseases (such as Renal Failure, among others). Renal Failure is a well-known source of False Positive (FP) in healthy patients by increasing SCC up to malignancy levels so, SCC can not be used to calculate risk.

Conclusions

ALTHOUGH SOME OF THE COMORBILITIES CAN VOID THE VALUES OF SOME TUMOR MARKERS, WE SUGGEST MALIGNANCY WITH A PROBABILITY OF 98.00%.

This report has been generated from the data entered on 30-08-2017 12:41:12 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Unknown Primary Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.4%, Specificity = 98.1%, PPV = 94.9%, NPV = 97.3%.

